Rituximab
This page contains brief information about rituximab and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Rituximab is approved to be used alone or with other drugs to treat:
- B-cell non-Hodgkin lymphoma (NHL) that is CD20 positive. It is used to treat:
- Follicular lymphoma that has relapsed or is refractory (doesn’t respond to treatment).
- Non-progressing NHL.
- NHL in patients who have not been treated.
- Chronic lymphocytic leukemia (CLL).
Rituximab is also being studied in the treatment of other conditions and types of cancer.
Rituximab is also available in a different form, combined with hyaluronidase. For more information, see the Drug Information Summary for Rituximab and Hyaluronidase Human.
More About Rituximab
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
MedlinePlus Information on Rituximab - A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Research Results and Related Resources
Approval Expanded for Venetoclax in Chronic Lymphocytic Leukemia
Drug Combination Improves Outlook for Some Patients with Chronic Lymphocytic Leukemia
Biological Therapies for Cancer
Study Suggests New Treatment Option for Some Lymphomas
Clinical Trials Accepting Patients
Find Clinical Trials for Rituximab - Check for trials from NCI's list of cancer clinical trials now accepting patients.